Indolent Plasma Cell Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Indolent Plasma Cell Myeloma

MalaCards integrated aliases for Indolent Plasma Cell Myeloma:

Name: Indolent Plasma Cell Myeloma 12
Indolent Myeloma 12 15
Plasma Cell Myeloma 12


External Ids:

Disease Ontology 12 DOID:9550
NCIt 50 C7150
UMLS 71 C2049069

Summaries for Indolent Plasma Cell Myeloma

Disease Ontology : 12 A multiple myeloma that is characterized by M protein in serum and/or urine and evidence of organ damage related the plasma cell neoplasm.

MalaCards based summary : Indolent Plasma Cell Myeloma, also known as indolent myeloma, is related to extramedullary plasmacytoma and amyloidosis. An important gene associated with Indolent Plasma Cell Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Mesna and Molgramostim have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are hematopoietic system and immune system

Related Diseases for Indolent Plasma Cell Myeloma

Diseases related to Indolent Plasma Cell Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 370)
# Related Disease Score Top Affiliating Genes
1 extramedullary plasmacytoma 30.6 MYOM2 IL6
2 amyloidosis 30.1 MYOM2 MEFV IL6 IL1B
3 bronchopneumonia 30.0 IL6 IL1B
4 graft-versus-host disease 29.9 IL6 IL1B IL1A
5 necrotizing fasciitis 29.9 MYOM2 IL6 IL1B
6 poems syndrome 29.9 MYOM2 IL6 IL1B
7 post-transplant lymphoproliferative disease 29.9 IL6 IL1R1 IL1A
8 dermatitis 29.7 IL6 IL1B IL1A
9 meningitis 29.7 IL6 IL1B IL1A
10 toxic shock syndrome 29.4 MYOM2 IL6 IL1R1 IL1B
11 respiratory failure 29.2 IL6 IL1R1 IL1B IL1A
12 myeloma, multiple 11.7
13 bone marrow cancer 11.2
14 plasmacytoma 10.4
15 lymphoma 10.4
16 plasma cell neoplasm 10.4
17 leukemia 10.4
18 plasmablastic lymphoma 10.4
19 b-cell lymphoma 10.4
20 lymphoproliferative syndrome 10.3
21 macroglobulinemia 10.3
22 plasma cell leukemia 10.3
23 leukemia, chronic lymphocytic 10.3
24 leukemia, acute myeloid 10.3
25 monoclonal gammopathy of uncertain significance 10.3
26 lymphoma, hodgkin, classic 10.3
27 myelodysplastic syndrome 10.3
28 lymphoplasmacytic lymphoma 10.3
29 streptococcal toxic-shock syndrome 10.2 MYOM2 IL6
30 osteosclerotic myeloma 10.2 MYOM2 IL6
31 lymphoma, non-hodgkin, familial 10.2
32 histiocytosis 10.2
33 myeloid leukemia 10.2
34 physiological polycythemia 10.2 IL6 IL1B
35 prosthetic joint infection 10.2 IL6 IL1B
36 periodontitis, chronic 10.2 IL6 IL1B
37 uremic pruritus 10.2 IL6 IL1B
38 anaerobic pneumonia 10.2 IL6 IL1B
39 ulcer of lower limbs 10.2 IL6 IL1B
40 transient arthritis 10.2 IL6 IL1B
41 suppurative periapical periodontitis 10.2 IL6 IL1B
42 bacterial conjunctivitis 10.2 IL6 IL1B
43 tracheitis 10.2 IL6 IL1B
44 carbuncle 10.2 IL6 IL1B
45 hypopyon 10.2 IL6 IL1B
46 eales disease 10.2 IL6 IL1B
47 tenosynovitis 10.2 IL6 IL1B
48 aortitis 10.2 IL6 IL1B
49 anthracosis 10.2 IL6 IL1B
50 lung abscess 10.2 IL6 IL1B

Graphical network of the top 20 diseases related to Indolent Plasma Cell Myeloma:

Diseases related to Indolent Plasma Cell Myeloma

Symptoms & Phenotypes for Indolent Plasma Cell Myeloma

MGI Mouse Phenotypes related to Indolent Plasma Cell Myeloma:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.8 IL1A IL1B IL1R1 IL6 LRRC3 MAP3K8
2 immune system MP:0005387 9.76 IL1A IL1B IL1R1 IL1RAP IL6 LRRC3
3 integument MP:0010771 9.5 IL1A IL1B IL1R1 IL1RAP IL6 MEFV
4 neoplasm MP:0002006 9.02 IL1A IL1B IL1R1 IL6 MAP3K8

Drugs & Therapeutics for Indolent Plasma Cell Myeloma

Drugs for Indolent Plasma Cell Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mesna Approved, Investigational Phase 4 3375-50-6 598
2 Molgramostim Investigational Phase 4 99283-10-0
Daratumumab Approved Phase 3 945721-28-8
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
Pomalidomide Approved Phase 3 19171-19-8
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
Acetaminophen Approved Phase 3 103-90-2 1983
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
Promethazine Approved, Investigational Phase 3 60-87-7 4927
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Phenylalanine Approved, Investigational, Nutraceutical Phase 3 63-91-2 6140
Cortisone Experimental Phase 3 53-06-5 222786
13 Immunoglobulins Phase 3
14 Antibodies, Monoclonal Phase 3
15 Antibodies Phase 3
16 Nitrogen Mustard Compounds Phase 3
17 Anti-Infective Agents Phase 3
18 Anti-Bacterial Agents Phase 3
19 Pharmaceutical Solutions Phase 3
20 Hypnotics and Sedatives Phase 3
21 Analgesics, Non-Narcotic Phase 3
22 Anti-Ulcer Agents Phase 3
23 Antacids Phase 3
24 Anesthetics Phase 3
Bismuth Phase 3 7440-69-9 16682734 105143
26 Analgesics Phase 3
27 Bismuth tripotassium dicitrate Phase 3
28 Anesthetics, Local Phase 3
29 Ranitidine bismuth citrate Phase 3
30 Histamine H2 Antagonists Phase 3
31 Antipyretics Phase 3
L-Alanine Nutraceutical Phase 3 56-41-7 5950
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
Clarithromycin Approved Phase 2 81103-11-9 84029
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Pamidronate Approved Phase 2 40391-99-9 4674
Lactulose Approved Phase 2 4618-18-2 11333
Magnesium oxide Approved Phase 2 1309-48-4 14792
Bisacodyl Approved Phase 2 603-50-9
Zoledronic Acid Approved Phase 2 118072-93-8 68740
Bismuth subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
Magnesium hydroxide Approved, Investigational Phase 2 1309-42-8
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
Abatacept Approved Phase 2 332348-12-6 10237
Mycophenolic acid Approved Phase 2 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
2 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation Recruiting NCT04566328 Phase 3 Bortezomib;Dexamethasone;Lenalidomide
3 A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma Recruiting NCT04270409 Phase 3 Isatuximab SAR650984;Lenalidomide;Dexamethasone
4 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Recruiting NCT03937635 Phase 3 Dexamethasone;Lenalidomide
5 A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma Active, not recruiting NCT00114101 Phase 3 Lenalidomide;Melphalan
6 A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders Active, not recruiting NCT00098475 Phase 3 Dexamethasone;Lenalidomide;Thalidomide
7 A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant Active, not recruiting NCT03319667 Phase 3 Isatuximab SAR650984;Bortezomib;Lenalidomide;Dexamethasone;Acetaminophen (paracetamol) or equivalent;Ranitidine or equivalent;Diphenhydramine or equivalent
8 Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Active, not recruiting NCT01863550 Phase 3 Bortezomib;Carfilzomib;Dexamethasone;Lenalidomide
9 An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy Active, not recruiting NCT00602641 Phase 3 Lenalidomide;Melphalan;Prednisone;Thalidomide
10 A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant Active, not recruiting NCT00644228 Phase 3 Bortezomib;Dexamethasone;Lenalidomide
11 A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma Active, not recruiting NCT02990338 Phase 3 Isatuximab;Pomalidomide;Dexamethasone
12 Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines Active, not recruiting NCT03275285 Phase 3 isatuximab SAR650984;carfilzomib;dexamethasone
13 Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM) Not yet recruiting NCT03941860 Phase 3 Ixazomib;Ixazomib Citrate;Lenalidomide
14 Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma Unknown status NCT02119468 Phase 1, Phase 2 ixazomib citrate;dexamethasone;pomalidomide
15 Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT01955434 Phase 2 Cyclophosphamide;Smac Mimetic LCL161
16 Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation Completed NCT02880228 Phase 2 Dexamethasone;Lenalidomide
17 Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma Completed NCT00450814 Phase 1, Phase 2 Cyclophosphamide
18 Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma Completed NCT00088855 Phase 2 Bortezomib;Pegylated Liposomal Doxorubicin Hydrochloride
19 A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma Completed NCT00066638 Phase 2 Romidepsin
20 A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL) Completed NCT01842308 Phase 1, Phase 2 Carfilzomib;Melphalan
21 A Phase 2 Study of AZD6244 in Multiple Myeloma Completed NCT01085214 Phase 2 Selumetinib
22 Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma Completed NCT00445692 Phase 2 Clarithromycin;Dexamethasone;Lenalidomide
23 Randomized Phase 2 Trial of Retreatment With Pomalidomide or Lenalidomide With Dexamethasone for Patients With Relapsed Myeloma Completed NCT01794039 Phase 2 Dexamethasone;Lenalidomide;Pomalidomide
24 Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM) Completed NCT01547806 Phase 2 Filgrastim;Plerixafor
25 Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT00966693 Phase 1, Phase 2 Dexamethasone;Lenalidomide;Thalidomide
26 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma Completed NCT00839956 Phase 2 Bortezomib;Vorinostat
27 Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma Completed NCT00793572 Phase 2 Bortezomib;Cyclosporine;Cyclosporine;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
28 A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease Completed NCT01903811 Phase 2 Carfilzomib;Dexamethasone
29 Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma Completed NCT01605032 Phase 2 Busulfan;Melphalan;Bortezomib
30 Daratumumab Infusion Acceleration Completed NCT02944565 Phase 2
31 A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma Completed NCT00941720 Phase 2 busulfan;cyclophosphamide
32 UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma Completed NCT00083382 Phase 2 Pamidronate;Thalidomide;Zometa
33 A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency Recruiting NCT04352205 Phase 2 Bortezomib;Dexamethasone;Lenalidomide;Thalidomide
34 Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma Recruiting NCT01415882 Phase 2 Cyclophosphamide;Dexamethasone;Ixazomib Citrate
35 A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation Recruiting NCT02700841 Phase 2 Melphalan
36 Phase 1-2 Trial Evaluating Anti-TGFβ Agent (SAR439459) or Pomalidomide in Combination With Isatuximab and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting NCT04643002 Phase 1, Phase 2 Isatuximab SAR650984;Dexamethasone;Pomalidomide;SAR439459
37 Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) Recruiting NCT02765854 Phase 2 Dexamethasone;Ixazomib;Lenalidomide
38 Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy Recruiting NCT03457142 Phase 2 Dexamethasone;Ixazomib Citrate
39 A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma Recruiting NCT03763162 Phase 2 Bortezomib;Dexamethasone;Ixazomib
40 Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study Recruiting NCT04205240 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
41 Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In Recruiting NCT03756896 Phase 2 Carfilzomib;Dexamethasone;Pomalidomide
42 Daratumumab for Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation Recruiting NCT03622775 Phase 2
43 Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT03417284 Phase 1, Phase 2 Melphalan Hydrochloride
44 A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study) Recruiting NCT03942224 Phase 2 Bortezomib;Dexamethasone;Ixazomib
45 Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma Recruiting NCT03841565 Phase 2 Dexamethasone;Pomalidomide
46 Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy Recruiting NCT03713294 Phase 2 Dexamethasone;Pomalidomide
47 Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab Recruiting NCT04407442 Phase 2 Azacitidine;Dexamethasone
48 A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma Recruiting NCT04508790 Phase 2 Dexamethasone;Leflunomide;Pomalidomide
49 A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Recruiting NCT03346135 Phase 2 Melphalan
50 Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Active, not recruiting NCT02086552 Phase 2 Lenalidomide;Sonidegib

Search NIH Clinical Center for Indolent Plasma Cell Myeloma

Genetic Tests for Indolent Plasma Cell Myeloma

Anatomical Context for Indolent Plasma Cell Myeloma

MalaCards organs/tissues related to Indolent Plasma Cell Myeloma:

Bone, T Cells, Bone Marrow, Kidney

Publications for Indolent Plasma Cell Myeloma

Articles related to Indolent Plasma Cell Myeloma:

(show all 21)
# Title Authors PMID Year
Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions. 61
28231967 2017
Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. 61
28636627 2017
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. 61
26160877 2015
[Successful steroid therapy for indolent myeloma with kidney injury due to direct infiltration of myeloma cells]. 61
26665616 2015
Ontology driven decision support systems for medical diagnosis - an interactive form for consultation in patients with plasma cell disease. 61
22874162 2012
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. 61
20730790 2010
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. 61
19181642 2009
Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. 61
17378894 2007
Cytodiagnosis of multiple myeloma presenting as orbital involvement: a case report. 61
16901345 2006
A smoldering/indolent myeloma with extensive abdominal presentation--case report. 61
16986300 2006
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. 61
12100153 2002
Amiodarone-induced bone marrow granulomas. 61
12109789 2002
Therapeutic application of thalidomide in multiple myeloma. 61
11740813 2001
Smoldering, asymptomatic stage 1, and indolent myeloma. 61
12057049 2000
Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. 61
10027725 1999
Coexistence of Polycythaemia Vera with Indolent Myeloma in the same Patient. 61
27406804 1997
[Aggressive transformation of an indolent myeloma with abdominal extramedullary plasmacytoma after 6-year period of observation]. 61
8028186 1994
[Evolution into indolent myeloma in a patient with benign monoclonal gammopathy after an eleven-year-interval]. 61
3404669 1988
Classification and prognostic variables in myelomatosis. 61
3901239 1985
Localized and indolent myeloma. 61
7407416 1980
Clinical classification of plasma cell myeloma. 61
1111462 1975

Variations for Indolent Plasma Cell Myeloma

Expression for Indolent Plasma Cell Myeloma

Search GEO for disease gene expression data for Indolent Plasma Cell Myeloma.

Pathways for Indolent Plasma Cell Myeloma

Pathways related to Indolent Plasma Cell Myeloma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.23 MAP3K8 IL6 IL1R1 IL1B IL1A
Show member pathways
4 12.57 MAP3K8 IL1RAP IL1R1 IL1B IL1A
Show member pathways
12.56 IL6 IL1R1 IL1B IL1A
Show member pathways
12.5 MAP3K8 IL1R1 IL1B IL1A
Show member pathways
12.49 IL6 IL1RAP IL1R1 IL1B IL1A
Show member pathways
12.43 MAP3K8 IL6 IL1B IL1A
Show member pathways
10 12.11 MEFV IL6 IL1B
11 12.1 IL6 IL1B IL1A
12 12.05 IL6 IL1B IL1A
Show member pathways
14 11.98 IL1R1 IL1B IL1A
15 11.97 MEFV IL6 IL1B
16 11.93 IL1R1 IL1B IL1A
Show member pathways
11.92 IL1R1 IL1B IL1A
18 11.87 IL6 IL1B IL1A
19 11.85 MAP3K8 IL6 IL1B
Show member pathways
11.85 IL6 IL1RAP IL1R1 IL1B IL1A
21 11.82 IL6 IL1B IL1A
22 11.8 IL6 IL1R1 IL1B
23 11.79 IL6 IL1B IL1A
24 11.78 IL6 IL1R1 IL1B IL1A
25 11.74 IL6 IL1B IL1A
Show member pathways
27 11.63 IL6 IL1B IL1A
28 11.62 IL6 IL1R1 IL1B IL1A
Show member pathways
11.54 IL6 IL1B IL1A
Show member pathways
11.52 IL6 IL1RAP IL1R1 IL1B
31 11.46 IL1RAP IL1R1 IL1A
32 11.39 IL6 IL1B IL1A
33 11.35 IL6 IL1B IL1A
34 11.26 IL6 IL1B
35 11.21 IL6 IL1B IL1A
36 11.19 IL6 IL1B
37 11.18 IL6 IL1B
38 11.07 IL1R1 IL1B
39 11.07 IL6 IL1B IL1A
40 10.97 IL1R1 IL1A
41 10.72 IL6 IL1B
42 10.61 IL6 IL1R1 IL1B IL1A
43 10.43 IL1B IL1A

GO Terms for Indolent Plasma Cell Myeloma

Biological processes related to Indolent Plasma Cell Myeloma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 IL6 IL1RAP IL1R1 IL1B IL1A
2 cellular response to lipopolysaccharide GO:0071222 9.71 IL6 IL1B IL1A
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.7 IL6 IL1RAP IL1B
4 cytokine-mediated signaling pathway GO:0019221 9.65 IL6 IL1RAP IL1R1 IL1B IL1A
5 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.58 IL1B IL1A
6 positive regulation of interleukin-2 production GO:0032743 9.58 IL1B IL1A
7 positive regulation of mitotic nuclear division GO:0045840 9.57 IL1B IL1A
8 negative regulation of neurogenesis GO:0050768 9.56 IL6 IL1B
9 regulation of nitric-oxide synthase activity GO:0050999 9.55 IL1B IL1A
10 positive regulation of glial cell proliferation GO:0060252 9.51 IL6 IL1B
11 positive regulation of vascular endothelial growth factor production GO:0010575 9.5 IL6 IL1B IL1A
12 positive regulation of neuroinflammatory response GO:0150078 9.49 IL6 IL1B
13 vascular endothelial growth factor production GO:0010573 9.48 IL6 IL1B
14 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.46 IL1R1 IL1B
15 positive regulation of interleukin-6 production GO:0032755 9.46 IL6 IL1RAP IL1B IL1A
16 positive regulation of immature T cell proliferation in thymus GO:0033092 9.43 IL1B IL1A
17 inflammatory response GO:0006954 9.43 MEFV IL6 IL1RAP IL1R1 IL1B IL1A
18 fever generation GO:0001660 9.4 IL1B IL1A
19 interleukin-1-mediated signaling pathway GO:0070498 9.02 MAP3K8 IL1RAP IL1R1 IL1B IL1A

Molecular functions related to Indolent Plasma Cell Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 IL6 IL1B IL1A
2 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.26 IL1RAP IL1R1
3 NAD(P)+ nucleosidase activity GO:0050135 9.16 IL1RAP IL1R1
4 interleukin-1 receptor activity GO:0004908 8.96 IL1RAP IL1R1
5 interleukin-1 receptor binding GO:0005149 8.8 IL1RAP IL1B IL1A

Sources for Indolent Plasma Cell Myeloma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....